AllianceBernstein’s Perspective Therapeutics CATX Stock Holding History

AllianceBernstein’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$230K	Hold	83,470	–	–	﹤0.01%	2991
2025 Q4	$230K	Hold	83,470	–	–	﹤0.01%	3009
2025 Q3	$286K	Hold	83,470	–	–	﹤0.01%	2955
2025 Q2	$287K	Buy	83,470 +33,780	+68%	+$89.2K	﹤0.01%	2936
2025 Q1	$106K	Hold	49,690	–	–	﹤0.01%	3062
2024 Q4	$159K	Hold	49,690	–	–	﹤0.01%	3068
2024 Q3	$663K	Buy	49,690 +25,370	+104%	+$337K	﹤0.01%	2521
2024 Q2	$242K	Buy	+24,320	New	+$352K	﹤0.01%	2986
2014 Q2	–	Sell	-50	Closed	-$1K	–	3433
2014 Q1	$1K	Buy	+50	New	+$509	﹤0.01%	3518

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's CATX Position: Q1 2026 in Review

AllianceBernstein held its Perspective Therapeutics (CATX) position steady in Q1 2026 at 83,470 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #2991.

AllianceBernstein first reported a position in CATX in Q1 2014 and has held it in 9 quarters since. The position peaked at $663K in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

AllianceBernstein held 83,470 shares of Perspective Therapeutics worth $230K as of Q1 2026.
AllianceBernstein left its Perspective Therapeutics share count unchanged in Q1 2026.
Perspective Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2991 holding.
AllianceBernstein first reported a position in Perspective Therapeutics in Q1 2014 and has held it in 9 quarters since.
AllianceBernstein's Perspective Therapeutics position peaked at $663K in Q3 2024.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.